NCT05379166View on ClinicalTrials.gov

Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 23, 2022

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2025

Conditions
Secondary Myelodysplastic SyndromeTherapy-Related Myelodysplastic Syndrome
Interventions
DRUG

Azacitidine

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Venetoclax

Given PO

Trial Locations (3)

43210

Ohio State University Comprehensive Cancer Center, Columbus

75390

University of Texas Southwestern Medical Center, Dallas

97239

Oregon Health & Science University, Portland

All Listed Sponsors
lead

Uma Borate

OTHER